Hemodynamic effects of fluoxetine in pulmonary arterial hypertension: an open label pilot study

In order to evaluate the therapeutic potential of fluoxetine in pulmonary arterial hypertension, 13 patients with pulmonary arterial hypertension underwent catheterization before and after 12 (N = 5) or 24 (N = 8) weeks fluoxetine therapy. No change was seen in the primary endpoint of pulmonary vasc...

Full description

Saved in:
Bibliographic Details
Published inPulmonary circulation Vol. 10; no. 4; pp. 1 - 4
Main Authors Sodimu, Adetoun, Bartolome, Sonja, Igenoza, Oluwatosin P., Chin, Kelly M.
Format Journal Article
LanguageEnglish
Published London, England SAGE Publications 01.10.2020
John Wiley & Sons, Inc
Wiley
Subjects
Pulmonary hypertension
Research Letter
right heart catheterization treatment
right heart catheterization treatment
pulmonary hypertension
Online AccessGet full text

Cover

More Information
Summary:In order to evaluate the therapeutic potential of fluoxetine in pulmonary arterial hypertension, 13 patients with pulmonary arterial hypertension underwent catheterization before and after 12 (N = 5) or 24 (N = 8) weeks fluoxetine therapy. No change was seen in the primary endpoint of pulmonary vascular resistance, other hemodynamic values, or any secondary endpoints.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2045-8940
2045-8932
2045-8940
DOI:10.1177/2045894020971954